US-based digital pathology platform Paige announced that three hospital systems in England have started real-time clinical use of its AI technology to detect and grade prostate cancer.
The three hospitals include North Bristol Trust Southmead Hospital, University Hospitals Coventry and Warwickshire, and Oxford University NHS Foundation Trust.
The hospitals added Paige’s AI technology to their standard of care as part of the Articulate Pro study, a collaborative project led by the University of Oxford.
Each hospital uses different digital pathology scanners and information systems from Paige, for serving diverse patient populations.
Articulate Pro study is designed to evaluate the potential of the company’s AI technology in improving patient outcomes amid increasing instances of prostate cancer.
Articulate Pro principal investigator professor Clare Verrill said: “The central focus of Articulate Pro is patients. We are striving towards our goal to safely and effectively ensure they benefit the most from powerful AI technology.
“With the multisite live use of The Paige Prostate Suite, we can systematically study benefits to patients in clinical settings.”
The Paige Prostate Suite is a system of diagnostic AI applications designed to help pathologists detect, grade, and measure tumours in prostate biopsies and tissue samples.
Pathologists at the three UK hospitals are evaluating how the Paige Prostate Suite impacts their clinical decision-making, pathology service delivery, and resource utilisation.
Paige said the use of its AI tech across multiple hospitals allows pathologists to assess how AI technology can best serve patients, histopathologists, and hospital systems in prostate cancer diagnosis.
Articulate Pro study is funded by the Accelerated Access Collaborative (AAC) Artificial Intelligence in Health and Care Award, overseen by the Department of Health and Social Care.
Articulate Pro Bristol lead, uropathologist Jon Oxley said: “It is a significant advancement that Paige’s AI applications have achieved a level of validation and performance that allows safe and effective live clinical use.
“Using Paige Prostate Suite alongside our standard of care has the promise to increase efficiency and improve reproducibility of results for patients.”
University Hospitals Coventry and Warwickshire uropathologist Bidisa Sinha said: “We believe AI can help to improve the accuracy and consistency of grading cancer and assist in the detection of small areas of cancer which are easy to miss.
“This is world-leading research being carried out at UHCW. We are proud to be a global leader in the field of digital and computational pathology.”
